Company intelligence / Profile preview
BIO3S Co., Ltd.
Gwangju, Jeollanam-do, South Koreabio3s.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
BIO3S has developed virus diagnostic technologies and patented soybean-derived protein lectins with potential anti-coronavirus activity. The company collaborates with Chonnam National University and focuses on both diagnostics and novel biotherapeutics for infectious diseases. No published clinical trial results as of June 2025.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Protein therapeutics (lectins)diagnostics technologies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Chonnam National University – research collaboration/investment-type partnership for virus diagnostic technology development
Beyond the preview
Go deeper on BIO3S Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BIO3S Co., Ltd..